NOVA MENTIS LIFE SCIENCE CORP To Carry Out 1-for-5 Reverse Stock Split On November 8th, 2024
Psyched: LSD For Major Depression, Canada's Large Scale Psilocybin Macrodose Trial, Treatments For Autism Spectrum Disorder And Multiple Sclerosis And More
Psychedelics And The Spectrum: Groundbreaking Study Details How One Firm Approaches Autism
Health Canada Grants Section 56 Exemption: Phase 2 Trial On Psilocybin For Leading Autism Cause
Nova Mentis Life Science Appoints Executive Chairman
First-Ever Clinical Trial On Magic Mushroom Therapy For Autism's Genetic Cause Receives Approval
Psychedelic Partnership To Test Psilocybin For FXS In First Phase 2 Clinical Trial
Psychedelics For FXS Symptoms: New Research Contract For Upcoming Phase 2 Clinical Trial
Magic Mushroom In A Pill? New Microdose Plans Enter Clinical Studies: Here's What Scientists Want To Learn
New Batch Of Psilocybin Microdose Capsules Is Ready, Learn All The Details
More Patent Applications For Psilocybin: Learn About NOVA's Psychedelic Treatments For Neurological Diseases
Nova Mentis NM-1001 Psilocybin Compound Gets DEA Approval For Export, Here's What Happened
Nova Mentis gets required U.S. DEA export approval for its psilocybin drug NM-1001
Nova Mentis Is Looking To Treat Autism With Psilocybin
This Psychedelics Penny Stock Is Up 55% After Successful Study On Microdosing For Autism
Nova Mentis names new CFO
BRIEF-Nova Mentis Files Genetic Neuroinflammatory Disease Patent
Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval
U.S. FDA Approves Nova Mentis Orphan Drug Application
Magic Mushrooms and Ecstasy: New Treatment For Autism Spectrum Disorders?
No Data